Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Next-Generation Sequencing in Medicine (Upcoming)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Epigenetic reprogramming to prevent genetic cardiomyopathy
Jamie R. Johnston, … , Daniel F. Selgrade, Elizabeth M. McNally
Jamie R. Johnston, … , Daniel F. Selgrade, Elizabeth M. McNally
Published January 4, 2021
Citation Information: J Clin Invest. 2021;131(1):e143684. https://doi.org/10.1172/JCI143684.
View: Text | PDF
Commentary

Epigenetic reprogramming to prevent genetic cardiomyopathy

  • Text
  • PDF
Abstract

Mutations in the gene that codes for lamin A/C (LMNA) are a common cause of adult-onset cardiomyopathy and heart failure. In this issue of the JCI, Guénantin and Jebeniani et al. identify impaired cardiomyocyte development and maturation as a prenatal feature in a model of laminopathy. Cardiomyocytes carrying the Lmna point mutation H222P misexpressed genes involved in the epithelial-mesenchymal transition and showed decreased methylation at the fourth lysine of histone H3 (H3K4). Notably, inhibiting lysine-specific demethylase 1 in the LMNA H222P mouse model treated this congenital form of cardiomyopathy and improved survival in utero. These data highlight early epigenomic modifications in lamin A/C-mediated pathology and indicate a unique therapeutic strategy for cardiomyopathy.

Authors

Jamie R. Johnston, Daniel F. Selgrade, Elizabeth M. McNally

×

Figure 1

The H222P Lmna mutation inhibits proper EMT in developing cardiomyocytes.

Options: View larger image (or click on image) Download as PowerPoint
The H222P Lmna mutation inhibits proper EMT in developing cardiomyocytes...
(A) In the normal developing heart, MESP1 is required for normal EMT. (B) In LmnaH222P/+ ESC-derived cardiomyocytes, activity of histone demethylase LSD1 results in decreased MESP1, resulting in reduced EMT. (C) Inhibition of LSD1 via a small molecule GSK1-LSD restores cardiac function in LmnaH222P/H222P mice. Restoration of proper chromatin accessibility represents an attractive therapeutic target to prevent cardiomyopathy in laminopathies. TF, transcription factor; RNAPol, RNA polymerase.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts